Article
Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype.
Multiple sclerosis and related disorders - 1 Jul 2020
Otto Ferdinand, Moser Tobias, Feige Julia, Seiberl Michael, Bieler Lara, Sellner Johann
Abstract excerpt
Immunoglobulin G (IgG) antibodies against myelin oligodendrocyte glycoprotein in serum denote an emerging autoimmune disorder of the central nervous system. Treatment trials have not been performed so far and anecdotal reports suggest that immunotherapies approved for multiple sclerosis (MS) may not be effective. We report favorable disease control with alemtuzumab, a CD52 depleting antibody approved for active...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.